

REMARKS

With entry of this amendment, claims 1 and 3 are pending. The claims have been amended to more particularly specify a preferred embodiment. Support for the amendment can be found throughout the specification, in particular at pages 4-5. No new matter has been added. Reconsideration is requested.

Claims 1-7 and 9-11 were rejected under 35 USC § 112, first paragraph, as not being enabled. The Examiner has taken the position that the claims are overly broad, and that it would require undue experimentation to practice the invention as claimed. Although Applicants do not agree, in order to expedite prosecution, claims 2, 4-7 and 9-11 have been cancelled, and claims 1 and 3 have been amended to be limited to a preferred embodiment. Accordingly, the claims recite a model mouse, and a method for screening a remedy comprising administering a substance to a model mouse, subject matter that the Examiner indicated was enabled. It is respectfully submitted that claims 1 and 3 are free of the rejection. Reconsideration and withdrawal of the rejection are accordingly requested.


Claims 1-7 and 9-11 have also been rejected under 35 USC § 112, second paragraph, as being indefinite. Claims 2, 4-7 and 9-11 have been cancelled. Claim 1 has been amended to delete the phrase "whose function of immunoglobulin Fc γ receptor IIB gene is deficient on its chromosome", which the Examiner considered to be indefinite. Claim 3 has been amended to include method steps which relate back to the preamble in a positive process. It is respectfully submitted that claims 1 and 3 are free of the indefiniteness rejection.

Application No. 10/009,950

All rejections having been addressed, it is respectfully submitted that this application is
in condition for allowance, and Notice to that effect is respectfully requested.

Respectfully submitted,

Date: 8/18/04



Ann S. Hobbs
Registration No. 36,830
VENABLE
P.O. Box 34385
Washington, D.C. 20043-9998
Telephone: (202) 962-4800

#571089v1